ArticleScientific reports2025
Network pharmacology identifies AKR1C3 and KYNU as potential targets of Astragalus Membranaceus and Ephedra in pediatric obesity-associated asthma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify and validate key target genes of Astragalus membranaceus and Ephedra in pediatric obesity-associated asthma using integrated bioinformatics and network pharmacology approaches, with the goal of informing potential therapeutic strategies. Gene expression datasets related to pediatric obesity (GSE205668, GSE104815) and asthma (GSE147878, GSE143303) were analyzed. Candidate genes were obtained by overlapping differentially expressed genes with known targets of Astragalus membranaceus and Ephedra. Machine learning algorithms and expression analyses were applied to refine the list of key genes. Two nomogram prediction models were constructed based on these genes and assessed for diagnostic efficacy. Subsequent analyses included functional enrichment, immune cell infiltration profiling, molecular docking, and validation through reverse transcription quantitative PCR (RT-qPCR). The genes AKR1C3 and KYNU were identified as key targets associated with both pediatric obesity and asthma. RT-qPCR results demonstrated significantly elevated expression of AKR1C3 and KYNU in samples from individuals with obesity-related asthma (P < 0.01). The developed nomogram models accurately predicted disease risk. Functional enrichment analysis indicated that these genes were co-enriched in pathways including allograft rejection in the context of obesity and primary immunodeficiency in the context of asthma. Immune cell profiling indicated alterations in 18 immune cell types in pediatric obesity and 5 in asthma. Molecular docking results indicated that kaempferol and apigenin exhibited strong binding affinities with AKR1C3, while canavanine effectively targeted KYNU, with a binding energy of - 9.5 kcal/mol between AKR1C3 and kaempferol. AKR1C3 and KYNU were identified and experimentally validated as potential therapeutic targets in pediatric asthma associated with obesity. These findings support the therapeutic relevance of A. membranaceus and Ephedra-derived compounds in modulating key molecular pathways implicated in this comorbid condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.